Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Pricing Practices In Canada, Germany May Stifle Innovation – USTR Report

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. Trade Representative cites Canadian procedures that allow "infringing" generic drugs on the market in adding the country to its IP "watch list." The report expresses concern about Germany's development of a reference pricing system, which would lump brands with generics.
Advertisement

Related Content

International Rx Price Study To Be Used In Negotiations With Developed Countries
International Rx Price Study To Be Used In Negotiations With Developed Countries

Topics

Advertisement
UsernamePublicRestriction

Register

PS059568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel